The big drugmaker provided a disappointing Q4 update.
News & Analysis: Pfizer
Some good news. Some bad news. And some complicated news.
Pfizer's U.S. generic drug subsidiary, Greenstone, is partnering with men's health provider Roman to provide Viagra to patients.
The drugmaker's planned metamorphosis failed to impress investors, but that wasn't its only headwind.
The healthcare giant is coming off a poor performance in 2019, where its share price fell 10%.
It was a trying year for the generic drug manufacturer. Can a combination with Pfizer help to soothe beleaguered investors?
The company's enviable product pipeline and attractive dividend make it too tempting to pass up.
These two healthcare giants have a lot going for them. But which one is better?
Pfizer’s recent dividend increase is just one of the many reasons to consider buying the company’s shares.
These are the best dividend-paying drugmakers on the market.